Regeneron Pharmaceuticals: Macular Degeneration trials

The registry lists 15 Macular Degeneration studies with Regeneron Pharmaceuticals as lead sponsor. 2 are open to participants now and 8 have results posted.

Phase 1 5Phase 2 5Phase 3 3Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult ParticipantsRecruitingNCT07230834Phase 1
• A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic AtrophyRecruitingNCT06541704Phase 3
• Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular DegenerationCompletedNCT04126317Phase 2Results posted
• Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal InjectionCompletedNCT02713204Phase 2Results posted
• Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)TerminatedNCT02418754Phase 2Results posted
• Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)CompletedNCT01722045Phase 4Results posted
• Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)CompletedNCT00964795Phase 3Results posted
• Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMDCompletedNCT00527423Phase 2Results posted
• Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)CompletedNCT00509795Phase 3Results posted
• Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)CompletedNCT00320788Phase 2Results posted
• An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World SettingWithdrawnNCT06398080
• Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMDCompletedNCT02061865Phase 1
• Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)CompletedNCT01997164Phase 1
• Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMDCompletedNCT00383370Phase 1
• Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMDCompletedNCT00320775Phase 1